Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Amortization of Deferred Charges (2016 - 2025)

Cumberland Pharmaceuticals' Amortization of Deferred Charges history spans 16 years, with the latest figure at $7100.0 for Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges fell 20.55% year-over-year to $7100.0; the TTM value through Dec 2025 reached $23185.0, down 18.11%, while the annual FY2025 figure was $23185.0, 18.11% down from the prior year.
  • Amortization of Deferred Charges for Q4 2025 was $7100.0 at Cumberland Pharmaceuticals, up from $5362.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $13833.0 in Q1 2021 and bottomed at $110.0 in Q4 2021.
  • The 5-year median for Amortization of Deferred Charges is $5361.0 (2025), against an average of $5946.1.
  • The largest annual shift saw Amortization of Deferred Charges tumbled 99.04% in 2021 before it soared 3199.09% in 2022.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $110.0 in 2021, then skyrocketed by 3199.09% to $3629.0 in 2022, then rose by 18.38% to $4296.0 in 2023, then soared by 108.01% to $8936.0 in 2024, then dropped by 20.55% to $7100.0 in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Amortization of Deferred Charges are $7100.0 (Q4 2025), $5362.0 (Q3 2025), and $5361.0 (Q2 2025).